These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8537075)

  • 1. [Antihypertensive effects of repeated oral administration of cilnidipine, a novel calcium antagonist, in 2K1C renal hypertensive dogs].
    Takahara A; Uchida H; Konda T; Dohmoto H; Yoshimoto R; Komori M; Morioka T; Ono I; Takata Y; Kato H
    Nihon Yakurigaku Zasshi; 1995 Oct; 106(4):279-87. PubMed ID: 8537075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
    Kanda A; Haruno A; Miyake H; Nagasaka M
    J Cardiovasc Pharmacol; 1992; 20(5):723-30. PubMed ID: 1280733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
    Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.
    Kojima S; Shida M; Yokoyama H
    Hypertens Res; 2004 Jun; 27(6):379-85. PubMed ID: 15253102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
    Konda T; Enomoto A; Matsushita J; Takahara A; Moriyama T
    Nephron Physiol; 2005; 101(1):p1-13. PubMed ID: 15886499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of haemodynamic responses to cilnidipine and nicardipine in an experimental model of acute congestive heart failure.
    Noguchi K; Matsuzaki T; Koyama T; Itomine T; Sakanashi M
    Clin Exp Pharmacol Physiol; 1998; 25(7-8):541-7. PubMed ID: 9673425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs.
    Oizumi K; Miyamoto M; Koike H
    Jpn J Pharmacol; 1990 Jun; 53(2):264-6. PubMed ID: 2200921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antihypertensive effects of long-term treatment with AE0047, a novel long-lasting calcium antagonist, in hypertensive models of rats and dogs].
    Kido H; Nishikawa M; Hayashi K; Kubo Y; Ebisu H; Egi Y; Shinyama H; Nakamura N
    Nihon Yakurigaku Zasshi; 1997 Jun; 109(6):291-301. PubMed ID: 9253776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute antihypertensive effects of calcium channel blockers are not affected by calcium supplementation in patients with essential hypertension.
    Sato K; Dohi Y; Miyagawa K; Kojima M
    Jpn Heart J; 1998 May; 39(3):347-53. PubMed ID: 9711186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
    Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effect of the new dihydropyridine calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in dogs.
    Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T
    Arzneimittelforschung; 1992 Apr; 42(4):513-8. PubMed ID: 1642675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.
    Matsuno A; Ide F; Tanaka H; Asano S; Miyawaki S; Uno T; Tanaka J; Nakaguchi H; Sasaki M; Murakami M; Fuke N
    Ir J Med Sci; 2009 Dec; 178(4):419-22. PubMed ID: 18841437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs.
    Takata Y; Kato H
    Arzneimittelforschung; 1986 Oct; 36(10):1464-71. PubMed ID: 3814208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
    Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
    Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs.
    Kageyama M; Nishimura K; Takada T; Miyawaki N; Yamauchi H
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):102-7. PubMed ID: 1708042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRN4884, a novel K channel opener: antihypertensive effects in conscious renal hypertensive dogs.
    Kawahara J; Jinno Y; Endo M; Izumi H; Takeuchi A; Izawa T
    J Cardiovasc Pharmacol; 1997 Jun; 29(6):814-9. PubMed ID: 9234664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
    Tanaka M; Sekioka R; Nishimura T; Ichihara A; Itoh H
    Diabetes Res Clin Pract; 2014 Dec; 106(3):504-10. PubMed ID: 25458339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilnidipine loaded poly (ε-caprolactone) nanoparticles for enhanced oral delivery: optimization using DoE, physical characterization, pharmacokinetic, and pharmacodynamic evaluation.
    Diwan R; Ravi PR; Agarwal SI; Aggarwal V
    Pharm Dev Technol; 2021 Mar; 26(3):278-290. PubMed ID: 33319618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.
    Sugiyama A; Satoh Y; Takahara A; Ando K; Nakamura Y; Hashimoto K
    Heart Vessels; 2005 May; 20(3):112-5. PubMed ID: 15912307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.